Sino Biopharmaceutical Enters Boehringer Ingelheim Partnership Worth Up to US$7 Billion

Sino Biopharmaceutical HKEX:1177 said on Wednesday it had entered into an option and license agreement with Germany's Boehringer Ingelheim for six pre-clinical oncology programs that could generate about $7 billion in milestone payments.